Philadelphia chromosome-positive acute lymphoblastic leukemia: Impact of imatinib treatment on remission induciton and allogeneic stem cell tranplantation

Tibor Kovacsovics, Richard Maziarz

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has been associated with the worst patient survival rates of the various acute leukemias. Imatinib mesylate is a novel therapeutic agent that targets the BCR-ABL tyrosine kinase, the molecular abnormality associated with Ph+ ALL. The combination of imatinib with chemotherapy has led to improved and durable treatment responses in adult patients with Ph+ ALL, including the elderly population. Hematopoietic stem cell transplantation has also integrated imatinib into its transplant strategies, with early data suggesting improved progression-free survival without clearly identifiable augmented toxicity. Second-generation tyrosine kinase inhibitors offer potentially even greater improvements on these excellent imatinib-associated outcomes. This review addresses the evolution of the management of Ph+ ALL and is intended to assist in the description of its new natural history.

Original languageEnglish (US)
Pages (from-to)343-351
Number of pages9
JournalCurrent Oncology Reports
Volume8
Issue number5
DOIs
StatePublished - Sep 2006

Fingerprint

Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Stem Cells
Protein-Tyrosine Kinases
Hematopoietic Stem Cell Transplantation
Therapeutics
Natural History
Disease-Free Survival
Leukemia
Survival Rate
Transplants
Drug Therapy
Imatinib Mesylate
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{fd05f368d29f41609e6989b6e057c735,
title = "Philadelphia chromosome-positive acute lymphoblastic leukemia: Impact of imatinib treatment on remission induciton and allogeneic stem cell tranplantation",
abstract = "Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has been associated with the worst patient survival rates of the various acute leukemias. Imatinib mesylate is a novel therapeutic agent that targets the BCR-ABL tyrosine kinase, the molecular abnormality associated with Ph+ ALL. The combination of imatinib with chemotherapy has led to improved and durable treatment responses in adult patients with Ph+ ALL, including the elderly population. Hematopoietic stem cell transplantation has also integrated imatinib into its transplant strategies, with early data suggesting improved progression-free survival without clearly identifiable augmented toxicity. Second-generation tyrosine kinase inhibitors offer potentially even greater improvements on these excellent imatinib-associated outcomes. This review addresses the evolution of the management of Ph+ ALL and is intended to assist in the description of its new natural history.",
author = "Tibor Kovacsovics and Richard Maziarz",
year = "2006",
month = "9",
doi = "10.1007/s11912-006-0056-y",
language = "English (US)",
volume = "8",
pages = "343--351",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "5",

}

TY - JOUR

T1 - Philadelphia chromosome-positive acute lymphoblastic leukemia

T2 - Impact of imatinib treatment on remission induciton and allogeneic stem cell tranplantation

AU - Kovacsovics, Tibor

AU - Maziarz, Richard

PY - 2006/9

Y1 - 2006/9

N2 - Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has been associated with the worst patient survival rates of the various acute leukemias. Imatinib mesylate is a novel therapeutic agent that targets the BCR-ABL tyrosine kinase, the molecular abnormality associated with Ph+ ALL. The combination of imatinib with chemotherapy has led to improved and durable treatment responses in adult patients with Ph+ ALL, including the elderly population. Hematopoietic stem cell transplantation has also integrated imatinib into its transplant strategies, with early data suggesting improved progression-free survival without clearly identifiable augmented toxicity. Second-generation tyrosine kinase inhibitors offer potentially even greater improvements on these excellent imatinib-associated outcomes. This review addresses the evolution of the management of Ph+ ALL and is intended to assist in the description of its new natural history.

AB - Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has been associated with the worst patient survival rates of the various acute leukemias. Imatinib mesylate is a novel therapeutic agent that targets the BCR-ABL tyrosine kinase, the molecular abnormality associated with Ph+ ALL. The combination of imatinib with chemotherapy has led to improved and durable treatment responses in adult patients with Ph+ ALL, including the elderly population. Hematopoietic stem cell transplantation has also integrated imatinib into its transplant strategies, with early data suggesting improved progression-free survival without clearly identifiable augmented toxicity. Second-generation tyrosine kinase inhibitors offer potentially even greater improvements on these excellent imatinib-associated outcomes. This review addresses the evolution of the management of Ph+ ALL and is intended to assist in the description of its new natural history.

UR - http://www.scopus.com/inward/record.url?scp=33748360705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748360705&partnerID=8YFLogxK

U2 - 10.1007/s11912-006-0056-y

DO - 10.1007/s11912-006-0056-y

M3 - Article

C2 - 16901395

AN - SCOPUS:33748360705

VL - 8

SP - 343

EP - 351

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 5

ER -